drugset / Trial / NCT07562022
A Study to Evaluate the Safety and Efficacy of SCTB35 in Combination With Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the efficacy and safety of SCTB35 in Combination With Lenalidomide in Patients With Relapsed or Refractory Follicular lymphoma (FL).
Timeline
- Start
- 2026-05
- Primary completion
- 2028-05
- Completion
- 2029-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Rituximab | Monoclonal antibody | — | Intravenous |
| Subject | SCTB35 | Unknown | — | Subcutaneous |
| Background | Lenalidomide | Other / unclassified | — | Oral |